Migration pathways of human glioblastoma cells xenografted into the immunosuppressed rat brain.
Diffuse invasion of the brain by tumor cells is a hallmark of human glioblastomas and a major cause for the poor prognosis of these tumors. This phenomenon is only partially reproduced by rodent models of gliomas that display a very high rate of proliferation and limited cell migration. We have analyzed the development of human glioblastoma cells (GL15) xenografted into the brain of immunosuppressed rats, in order to define the characteristics of tumor cell invasion. As identified by the specific immunolabeling of the tumor cells for the human HLA-ABC antigen, GL15 tumors reproduced the three types of intraparenchymal invasion observed in patients. First, a majority of multipolar tumor cells intermingled rapidly and profusely with host neural cells in the margin of the injection site. This progressively enlarging area was principally responsible for the tumor growth over time. Second, in the gray matter, columns of thin bipolar tumor cells aligned along capillary walls. Third, in the white matter, elongated bipolar isolated tumor cells were observed scattered between axonal fibers. The maximum migration distances along white matter fibers remained significantly higher than the maximum migration distances along blood vessels, up to two months after injection. Development of the tumor was associated with a significant increase of vascularization in the area of tumor spread. Xenografting of human GL15 glioblastoma cells into the immunosuppressed rat brain allowed to differentiate between the three classical types of invasion identified in the clinic, to quantify precisely the distances of migration, and to evaluate cell morphology for each of these routes. The present results support the existence of host/tumor cells interactions with specific characteristics for each type of invasion.
Guillamo
J S
JS
INSERM Unité 421, IM3, Faculté de Médecine, Créteil, France.
Lisovoski
F
F
Christov
C
C
Le Guérinel
C
C
Defer
G L
GL
Peschanski
M
M
Lefrançois
T
T
D000818:Animals; D000951:Antigens, Neoplasm / Q000032:analysis; D015415:Biomarkers; D001921:Brain / Q000473:pathology*; D001932:Brain Neoplasms / Q000098:blood supply / Q000473:pathology*; D016380:Brain Tissue Transplantation; D002196:Capillaries / Q000473:pathology; D002465:Cell Movement; D016572:Cyclosporine / Q000633:toxicity; D005909:Glioblastoma / Q000098:blood supply / Q000473:pathology*; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000633:toxicity; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009368:Neoplasm Transplantation; D014411:Neoplastic Stem Cells / Q000473:pathology / Q000637:transplantation*; D009389:Neovascularization, Pathologic / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D014183:Transplantation, Heterologous / Q000473:pathology*; D014407:Tumor Cells, Cultured / Q000473:pathology / Q000637:transplantation
D000951:Antigens, Neoplasm; D015415:Biomarkers; D006680:HLA Antigens; D007166:Immunosuppressive Agents; D016572:Cyclosporine